Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. I. Protective mechanism

Journal of Neurosurgery

Volumn 85, Issue 6, 1996, Pages 1102-1107

  Yanaka, Kiyoyuki ^a   Spellman, Stephen R ^a   Mccarthy, James B ^a   Oegema Jr , Theodore R ^a   Low, Walter C ^a   Camarata, Paul J ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Neurology/Neurosurgery   (United States)

Author keywords

adhesion molecules; cerebral ischemia; heparin; leukocyte; rat

Indexed keywords

CHONDROITIN SULFATE; DEXTRAN SULFATE; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE;

ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; CELL ADHESION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE ADHERENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TISSUE INJURY;

EID: 0029857294     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.85.6.1102     Document Type: Article

References (51)

1. Anderson DC, Miller LJ, Schmalsteig FC, et al: Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions; structure-function assessments employing subunit-specific monoclonal antibodies. J Immunol 137: 15-27, 1986
2. Andersson LO, Barrowcliffe TW, Holmer E, et al: Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb Res 15:531-541, 1979
3. Arfors KE, Key K. Sulfated polysaccharides in inflammation. J Lab Clin Med 121:201-202, 1993 (Editorial)
4. Barone FC, Hillegass LM, Price WJ, et al: Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histology verification. J Neurosci Res 29:336-345, 1994
5. Bârzu T, Van Rijn JLML, Petitou M, et al: Endothelial binding sites for heparin. Specifity and role in heparin neutralization. Biochem J 238:847-854, 1986
6. Bazzoni G, Nuñes AB, Mascellani G, et al: Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121: 268-275, 1993
7. Bevilacqua MP, Nelson RM: Selectins. J Clin Invest 91: 379-387, 1993
8. Bevilacqua MP, Nelson RM, Mannori G, et al: Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 45:361-378, 1994
9. Bowes MP, Zivin JA, Rothlein R: Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 119:215-219, 1993
10. Bradley PP, Priebat DA, Christensen RD, et al: Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209, 1982
11. Butcher EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033-1036, 1991
12. Chen H, Chopp M, Zhang RL, et al: Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 35:458-463, 1994
13. Chopp M, Zhang RL, Chen H, et al: Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 25:869-876, 1994
14. Clark WM, Madden KP, Rothlein R, et al: Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg 75:623-627, 1991
15. Clowes AW, Karnowsky MJ: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625-626, 1977
16. Diamond MS, Alon R, Parkos CA, et al: Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 130:1473-1482, 1995
17. Feuerstein GZ, Liu T, Barone FC: Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 6:341-360, 1994
18. Fisher CM: Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology 11:119-126, 1961
19. Granger DN: Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 255: H1269-H1275, 1988
20. x oligosaccharides and the predominance of sulfate in this interaction demonstrated by binding studies with a series of lipid-linked oligosaccharides. Biochem Biophys Res Commun 188:244-251, 1992
21. Guyton JR, Rosenberg RD, Clowes AW, et al: Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 46:625-634, 1980
22. Hemker HC, Béguin S: Standard and method independent units for heparin anticoagulant activities. Thromb Haemost 70: 724-728, 1993
23. Hynes RO: Integrins: a family of cell surface receptors. Cell 48: 549-554, 1987
24. 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol 118:431-444, 1992
25. Kochanek PM, Hallenbeck JM: Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 23:1367-1379, 1992
26. Lasky LA: Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258:964-969, 1992
27. Ley K, Cerrito M, Arfors KE: Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260:H1667-H1673, 1991
28. Lindahl U, Lidholt K, Spillmann D, et al: More to "heparin" than anticoagulation. Thromb Res 75:1-32, 1994
29. Marcum JA, Rosenberg RD: Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin Thromb Hemost 13:464-474, 1987
30. Martz E, Benacerraf B: Inhibition of immune cell-mediated killing by heparin. Clin Immunol Immunopathol 1:533-536, 1973
31. Matsuo Y, Onodera H, Shiga Y, et al: Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 656:344-352, 1994
32. Mitruka BM, Rawnsley HM: Clinical, Biochemical and Hematological Reference Values in Normal Experimental Animals. New York: Masson, 1977
33. Nelson RM, Cecconi O, Roberts WG, et al: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258, 1993
34. Nilsson-Ehle P, Garfinkel AS, Scholz MC: Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 49: 667-693, 1980
35. Norgard-Sumnicht KE, Varki NM, Varki A: Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science 261:480-483, 1993
36. Robinson DS: The function of plasma triglycerides in fatty acid transport. Comp Biochem 18:51-57, 1970
37. Ruoslahti E: Integrins. J Clin Invest 87:1-5, 1991
38. Schmid-Schönbein GW, Engler RL: Granulocytes as active participants in acute myocardial ischemia and infarction. Am J Cardiovasc Pathol 1:15-30, 1986
39. Smith DR, Ducker TB, Kempe LG: Temporary experimental intracranial vascular occlusion. Effect of massive doses of heparin on brain survival. J Neurosurg 30:537-544, 1969
40. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990
41. Sternbergh WC Jr, Sobel M, Makhoul RG: Heparinoids with low anticoagulant potency attenuate postischemic endothelial cell dysfunction. J Vasc Surg 21:477-483, 1995
42. Sundt TM Jr, Waltz AG: Hemodilution and anticoagulation. Effects on the microvasculature and microcirculation of the cerebral cortex after arterial occlusion. Neurology 17:230-238, 1967
43. Suzuki Y, Toda Y, Tamatani T, et al: Sulfated glycolipids are ligands for a lymphocyte homing receptor, L-selectin (LECAM-1), binding epitope in sulfated sugar chain. Biochem Biophys Res Commun 190:426-434, 1993
44. Sy MS, Schneeberger E, McCluskey R, et al: Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol 82:23-32, 1983
45. Tanaka Y, Adams DH, Hubscher S, et al: T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 361:79-82, 1993
46. Weksler BB, Lewin M: Anticoagulation in cerebral ischemia. Stroke 14:658-663, 1983
47. Yanaka K, Camarata PJ, Spellman SR, et al: Optimal timing of hemodilution for brain protection in a canine model of focal cerebral ischemia. Stroke 27:906-912, 1996
48. Yanaka K, Camarata PJ, Spellman SR, et al: Synthetic fibronectin peptides and ischemic brain injury after transient middle cerebral artery occlusion in rats. J Neurosurg 85:125-130, 1996
49. Yanaka K, Spellman SR, McCarthy JB, et al: Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window. J Neurosurg 85: 1108-1112, 1996
50. Zea Longa E, Weinstein PR, Carlson S, et al: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91, 1989
51. Zhang RL, Chopp M, Jiang N, et al: Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 26:1438-1443, 1995